Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

Key Takeaways VRTX gains EU approval for Alyftrek to treat CF patients aged six and above with non-class I mutations. Alyftrek offers once-daily dosing and potential benefits over Trikafta, including improved CFTR function. Alyftrek sales reached $53.9M in Q1 2025, with management expecting stronger uptake in H2 2025.Vertex Pharmaceuticals (VRTX) announced that the European Commission has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for treating people with cystic fibrosis (“CF”) aged six year ...